Product News | Nucleoside Drugs and APIs: for the Teatment of Hepatitis B

• share:
• 
• 
• 
• 
• 
• 

The nucleoside drugs has been instrumental in the treatment of chronic hepatitis B. In the past two decades, research has continued to develop and nucleoside analogues have emerged, and there are now five nucleoside analogues, including lamivudine, adefovir, tipifovir, entecavir and tenofovir, and people have gained a deeper understanding and more experience in the antiviral treatment of hepatitis B.

With the end of the protection period of various original drugs, the research and development of generic drugs in China has entered a brand new stage, and clinicians and patients have more choices compared with the past.

 

CHEMENU is a manufacturer of nucleoside and nucleotide pharmaceutical ingredients, and we have various intermediates for sale to provide basic materials for the research of nucleoside drugs in the world. Read on to learn more about how nucleosides are therapeutic.

 

 

 

 

Antiviral treatment for chronic hepatitis B is a global consensus. Although hepatitis B virus does not directly destroy liver cells, liver cells are the host site of hepatitis B virus, and once the body's immune system recognizes hepatitis B virus, an immune-mediated response is bound to occur, causing liver cell damage, abnormal liver function, and even cirrhosis, liver failure, and possibly liver cancer. Therefore, various guidelines from around the world emphasize the necessity and importance of antiviral therapy for chronic hepatitis B.

 

There are two major categories of clinically applied anti-hepatitis B virus drugs, one is nucleoside analogues and the other is a-interferon, the latter has a tendency to gradually decrease in clinical application because of the large side effects and inconvenient administration, and the more common application is nucleoside analogues.

 

 

2'-O-(2-Methoxyethyl)guanosine

CAS：473278-54-5

 

 

A nucleoside analogue is a nucleoside whose structure has been artificially modified, and this modification is usually performed on pentoses. The bases corresponding to lamivudine, telbivudine and entecavir are cytosine, thymine and guanine, respectively, and the bases corresponding to adefovir and tenofovir are both adenine. The antiviral mechanism of nucleoside analogues is to block the replication of virus by inhibiting the activity of HBV DNA polymerase. Because of the high similarity between the nucleoside structure of the drug and the viral polymerase, they can competitively bind to the viral polymerase, thus reducing the enzyme activity and terminating the extension of the viral DNA chain.

 

 

The guidelines for the prevention and treatment of hepatitis B developed by the American College of Hepatology, the European College of Hepatology and the Asia Pacific Society of Hepatology all put forward the concept of "first-line drugs", i.e., first-line drugs should be preferred in antiviral therapy, and the recommended first-line drugs are entecavir, tenofovir and pegylated interferon.

 

People should put safety and efficacy in the first place when choosing drugs, and be guided by guidelines, taking into account price, health insurance and accessibility of drugs. In terms of drug safety, the focus should be on side effects and teratogenicity. China has conducted quality consistency evaluation of approved generic drugs in batches according to the principle of consistent quality and efficacy with the original drug, which provides new help for our drug selection.

 

 

Antiviral therapy for chronic hepatitis B is the key to treatment, and nucleoside analogues are effective antiviral drugs. Please contact CHEMENU to get more products and the quote.